LOS ANGELES, June 16, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Eco Science Solutions, Inc. (“Eco Science” or the “Company”) (Other OTC:ESSI) for possible violations of federal securities laws between May 1, 2017 and May 19, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 24, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Eco Science made materially false and misleading statements, and/or failed to disclose that its plan for strategic acquisitions lacked veracity; consequently, the Company’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On May 19, 2017, the U.S. Securities and Exchange Commission announced a temporary suspension of trading Eco Science securities “because of concerns regarding the accuracy and adequacy of publicly disseminated information concerning, among other things, ESSI’s proposed acquisition of Ga-Du Bank, Inc.”
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles devoted to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Anta Sports Expands Global Footprint With Strategic Puma Stake
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 



